VEGFA and hepatocellular carcinoma: Recently, the combination of atezolizumab, a fully humanized anti-programmed death-ligand 1 antibody, and bevacizumab, a vascular endothelial growth factor (VEGF) targeting antibody, (Atez/Bev) has been approved as the standard first-line systemic therapy for HCC, based on the IMbrave 150 trial8,9.